JAAD Case Reports (Sep 2023)
Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib
- Christopher J. Fay, BA,
- Dorsa Moslehi, BA,
- Christopher Iriarte, MD,
- Timothy M. Dang, MD,
- Cesar A. Virgen, MD, PhD,
- Eleanor Russell-Goldman, MD, PhD,
- Nicole R. LeBoeuf, MD, MPH
Affiliations
- Christopher J. Fay, BA
- Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Dorsa Moslehi, BA
- Harvard Medical School, Boston, Massachusetts
- Christopher Iriarte, MD
- Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
- Timothy M. Dang, MD
- Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
- Cesar A. Virgen, MD, PhD
- Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
- Eleanor Russell-Goldman, MD, PhD
- Harvard Medical School, Boston, Massachusetts; Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
- Nicole R. LeBoeuf, MD, MPH
- Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Correspondence to: Nicole R. LeBoeuf, MD, MPH, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, 450 Brookline Ave, Boston, MA 02115.
- Journal volume & issue
-
Vol. 39
pp. 74 – 77